What one share of Fractyl Health holds
We are a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (“T2D”). Our Revita® and Rejuva® candidates are designed to target root causes of metabolic diseases, allowing us to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease.
Fractyl Health’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.81 |
|---|---|
| Cash and investments | $0.30 |
| Debt | $0.19 |
| Book value | −$0.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.06 | −$45.29 | $0.17 | −$20.75 | — | −$154.36 |
| 2024 | $0.00 | −$1.62 | $0.04 | −$1.55 | — | $0.58 |
| 2025 | $0.00 | −$1.86 | $0.01 | −$1.20 | — | $0.06 |
Common questions about Fractyl Health
How much does one share of Fractyl Health earn?
Over the last 12 months, Fractyl Health lost $0.81 for each share.
Does Fractyl Health pay a dividend?
Fractyl Health didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Fractyl Health’s book value per share?
Fractyl Health’s book value is negative (−$0.01 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Fractyl Health have?
Each share of Fractyl Health has $0.30 of cash and investments and $0.19 of debt, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.